What is Matinas BioPharma Holdings Inc (MTNB) stock price today?

Matinas BioPharma Holdings Inc (MTNB) currently trades at $0.61 per share. The stock has a market capitalization of $3.91M and a P/E ratio of —x.

Is MTNB stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Matinas BioPharma Holdings Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -22.54.

Is Matinas BioPharma Holdings Inc financially healthy?

Matinas BioPharma Holdings Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -22.54 places it in the distress.

MTNB

Matinas BioPharma Holdings Inc

NYSE MKT: MTNB · HEALTHCARE · BIOTECHNOLOGY

$0.61

+2.87% today

Updated 2026-04-29

Market cap

$3.91M

P/E ratio

—

P/S ratio

34.81x

EPS (TTM)

$-2.00

Dividend yield

—

52W range

$0 – $3

Volume

0.0M

Market cap

$3.91M

P/E ratio

—

P/S ratio

34.81x

EPS (TTM)

$-2.00

Dividend yield

—

52W range

$0 – $3

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-22.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$30.00

+4793.96%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.36x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -22.54 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-1.51M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$3.19M	$1.10M	$0.00	$0.00	$0.00
Net income	$-21.00M	$-22.94M	$-24.25M	$-10.35M	$-1.91M
EPS	—	—	—	—	$-2.00
Free cash flow	$-20.05M	$-15.50M	$-15.88M	$-7.01M	$-1.51M
Profit margin	-658.63%	-2,093.25%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MTNB	$3.91M	24	3.7	3.0	5.0	6.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Matinas BioPharma Holdings Inc trades at $0.61. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -22.54, it sits in the distress.

Frequently asked questions

What is Matinas BioPharma Holdings Inc's stock price?

Matinas BioPharma Holdings Inc (MTNB) trades at $0.61.

Is Matinas BioPharma Holdings Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Matinas BioPharma Holdings Inc (MTNB)?

The analyst target price is $30.00, representing +4794.0% upside from the current price of $0.61.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-22.54 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

Quick metrics

P/S ratio34.81x

ROE-166.60%

Beta1.40

50D MA$0.58

200D MA$1.04

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MTNB vs LLY →MTNB vs JNJ →MTNB vs ABBV →Stock screener →